Cox Christopher T. - 28 Mar 2022 Form 3/A - Amendment Insider Report for Adagio Therapeutics, Inc. (IVVD)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3/A - Amendment
Accepted by SEC
06 Apr 2022, 17:02:27 UTC
Original report date
30 Mar 2022
Next SEC filing
28 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christopher Cox

Key filing fact

Cox Christopher T. filed Form 3/A - Amendment for Adagio Therapeutics, Inc. (IVVD) on 06 Apr 2022.

Key facts

  • This page summarizes Cox Christopher T.'s Form 3/A - Amendment filing for Adagio Therapeutics, Inc. (IVVD).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 06 Apr 2022, 17:02.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IVVD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
679,822
Date
28 Mar 2022
Ownership
See footnotes
Footnotes
F1, F2, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This Form 3 is not being filed in connection with the acquisition or disposition of any securities of the Issuer.

Footnote F2

359,662 shares of Common Stock are held directly by Population Health Equity Partners III, L.P. ("PH III") and a further 320,160 shares of Common Stock are held directly by Population Health Equity Partners VII, L.P. ("PH VII"). PH III is controlled by Population Health Equity Partners III GP, LLC ("PH III GP"), its general partner, and PH VII is controlled by Population Health Equity Partners VII GP, LLC ("PH VII GP"), its general partner. Clive Meanwell and Christopher Cox are the sole managing members of both PH III GP and PH VII GP and may be deemed to have shared voting and dispositive power with respect to the shares of Common Stock held directly by PH III and PH VII. Clive Meanwell and Christopher Cox disclaim beneficial ownership of the shares held directly by PH III and PH VII, except to the extent of their pecuniary interests therein, if any. Clive Meanwell has filed a separate Form 3 in respect of the Issuer.

Footnote F3

On March 28, 2022, PH III, PH VII and Clive Meanwell ("PH") and (i) Mithril II LP ("Mithril"), (ii) M28 Capital Management LP (together with certain of its affiliates, "M28"), (iii) Polaris Venture Partners V, L.P. and certain affiliates (collectively, "Polaris") and (iv) Adimab, LLC, orally agreed to coordinate and cooperate in certain of their activities with regard to the Issuer, which agreement was subsequently memorialized, also on March 28, 2022, in an email circulated among representatives of such persons. That agreement provides that each such person will vote its shares of Common Stock in favor of the election of certain director nominees at the Issuer's 2022 annual meeting. By virtue of such agreement, the forgoing persons may be deemed to be part of a "group" (within the meaning of Section 13(d)(3) of the Exchange Act) comprised of such persons.

Footnote F4

The Reporting Persons expressly disclaim beneficial ownership over any Common Stock that they may be deemed to beneficially own solely by reason of the agreement reached among Population Health, Mithril, M28, Polaris and Adimab, LLC, and beneficial ownership of any securities of the Issuer other than those reported on this Form 3 in which they have a direct pecuniary interest. This filing shall not be deemed an admission that the Reporting Persons are 10% shareholders for purposes of Section 16 of the Exchange Act.

SEC remarks

This amended Form 3 is being filed (1) to revise the entity name for the Reporting Persons from "Population Health Equity Partners" to "Population Health Partners, L.P." and (2) for the purpose of including the joint filers as signatories, who were omitted in the original filing pending receipt of EDGAR codes.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .